Table 5 Time-varying HR estimates^a from a fixed-effects NMA for DMFS (p1 = 0, p2 = −0.5, scale, shape ×1) in patients with stage II–IV melanoma

NIVO vs. OBS/PBO

0.67 (0.48–0.93)

0.77 (0.50–1.20)

0.83 (0.46–1.49)

0.87 (0.42–1.76)

NIVO vs. DAB+TRAM

1.06 (0.68–1.63)

0.65 (0.37–1.14)

0.51 (0.24–1.07)

0.44 (0.17–1.08)

NIVO vs. IPI (10 mg/kg)

0.80 (0.61–1.06)

0.88 (0.60–1.28)

0.93 (0.55–1.56)

0.96 (0.50–1.84)

NIVO vs. IFN

0.73 (0.51–1.05)

0.80 (0.51–1.27)

0.84 (0.47–1.53)

0.86 (0.42–1.78)